You are here:

Home
NICE Guidance
Conditions and diseases
Blood and immune system conditions
Blood and bone marrow cancers

Rituximab for the treatment of relapsed or refractory stage 3 or 4 follicular non-Hodgkin's lymphoma

Technology appraisal guidance
Reference number: TA137
Published: 27 February 2008

Guidance
Tools and resources
Information for the public
Evidence
History

Consultee and commentator comments on the ACD

Joint comment from British Society for Haematology and the Royal College of Physicians/Royal College of Pathologists Intercollegiate Committee in Haematology
Joint comment from NCRI Lymphoma Clinical Studies Group, Royal College of Physicians, the Royal College of Radiologists, the Joint Collegiate Council for Oncology and the Association of Cancer Physicians
Roche
Royal College of Nursing
Royal College of Pathologists
Welsh Assembly Government

This page was last updated: 30 March 2010